Article Information
History
- January 4, 2023.
Article Versions
- Version 1 (January 3, 2023 - 07:07).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Rui Songa,#,
- Gang Zengb,#,
- Jianxing Yub,
- Xing Mengb,
- Xiaoyou Chena,
- Jing Lic,
- Xiaoliang Xied,e,
- Xiaojuan Lianc,
- Zhiyun Zhanga,
- Yunlong Caod,e,*,
- Weidong Yinb,* and
- Ronghua Jina,*
- aBeijing Ditan Hospital, Capital Medical University, Beijing 100015, P.R. China
- bSinovac Biotech Co., Ltd., Beijing 100085, P.R. China
- cSinovac Life Sciences Co., Ltd., Beijing 102601, P.R. China
- dBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, P.R. China
- eChangping Laboratory, Beijing 102206, P.R. China
- ↵*Corresponding to: Dr. Yunlong Cao,
No. 5 Yiheyuan Road, Biomedical Pioneering Innovation Center, Peking University, Haidian District, Beijing 100871, P.R. China. Tel.: +86 010 66388827; Fax: +86 010 62767408. E-mail: yunlongcao{at}pku.edu.cn, Dr. Weidong Yin,
No.39, Shangdi West Road, Sinovac Biotech Ltd., Haidian District, Beijing 100085, P.R. China. Tel.: +86 010 82799373; E-mail: yinwd{at}sinovac.com, Dr. Ronghua Jin,
No.8, Jingshun East Street, Beijing Ditan Hospital, Chaoyang District, Beijing 100015, China. Tel.: +86 010 84322000; E-mail: 93353503{at}qq.com
↵# These authors contributed equally to this work.
Posted January 04, 2023.
Post-Exposure Prophylaxis with SA58 (anti-COVID-19 monoclonal antibody) Nasal Spray for the prevention of symptomatic Coronavirus Disease 2019 in healthy adult workers: A randomized, single-blind, placebo-controlled clinical study
